The US Food and Drug Administration (FDA) has granted approval to medical solutions provider Boston Scientific’s Resonate line of implantable cardioverter defibrillator (ICD) and cardiac resynchronisation therapy defibrillator (CRT-D) systems.

The approval covers the devices’ new features such as SmartCRT technology with Multisite Pacing capability and compatibility with the HeartLogic Heart Failure Diagnostic Service.

The technology is meant for multi-electrode pacing, while HeartLogic is used to improve heart failure (HF) management.

The entire line of Resonate devices are powered by Boston Scientific’s EnduraLife Battery technology.

EnduraLife comes with two-times the usable battery capacity, which is considered to be useful to meet the lifelong needs of patients undergoing ICD or CRT therapy.

“We are changing the treatment landscape by combining industry-leading device longevity with innovative solutions that will provide clinicians with tools to manage heart failure more effectively.”

Boston Scientific Rhythm Management and Global Health Policy senior vice-president and chief medical officer Kenneth Stein said: “We are changing the treatment landscape by combining industry-leading device longevity with innovative solutions that will provide clinicians with tools to manage heart failure more effectively.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Our post-approval studies for the HeartLogic service, including MANAGE-HF, will gather additional evidence to illustrate how these alerts, which detect impending heart failure decompensation, can improve patient outcomes.”

The ability of SmartCRT technology to enhance response to the CRT therapy was demonstrated in the SMART Registry, SmartCRT and SMART-MSP clinical trials.

In February, Boston Scientific secured the CE Mark and started commercialising the Resonate ICD and CRT-D systems.